Calliditas plans to file for full approval for rare kidney disease drug following PhIII data

Katherine Lewin

News Reporter

Calliditas believes Phase III confirmatory data it released Sunday for its oral steroid to treat a rare kidney disease could be the final piece needed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Calliditas plans to file for full approval for rare kidney disease drug following PhIII data

Katherine Lewin

News Reporter

Sign up to read this article for free.

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

FDA approves subcutaneous version of Bristol Myers' Opdivo

Sofinnova outlines $550M fund after IPOs and M&A deals

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

WuXi AppTec will sell cell and gene therapy business to private equity firm

Cal­lid­i­tas plans to file for full ap­proval for rare kid­ney dis­ease drug fol­low­ing PhI­II da­ta

Katherine Lewin

News Reporter

Sign up to read this article for free.

more like this

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Calliditas plans to file for full approval for rare kidney disease drug following PhIII data

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

FDA approves subcutaneous version of Bristol Myers' Opdivo

Sofinnova outlines $550M fund after IPOs and M&A deals

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

WuXi AppTec will sell cell and gene therapy business to private equity firm